Vyant Bio

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded in 1999 and is headquartered in Cherry Hill, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company's stock will cease trading on the OTC, and the holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, pursuant to and in accordance with the Plan of Dissolution.

Vyant Bio Provides Update on Winddown Activities

CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”).

Vyant Bio Announces Stockholder Approval of Plan of Dissolution

CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to an Asset Purchase Agreement dated July 13, 2023.

Vyant Bio Announces Completion of StemoniX Asset Sale

CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special Meeting”) was reconvened resulting in the approval of the sale of all or substantially all of the assets of the Company.

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders

CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the “Proxy Statement”).

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders

CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the “Proxy Statement”).

Vyant Bio Announces Adjournment of Special Meeting of Stockholders

—Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrain™ Intellectual Property from StemoniX, Along With Expert Scientific Team and Advanced R&D and Manufacturing Facility in Minnesota— —AxoSim to Begin Offering microBrain Products and Services Under Interim Distribution Agreement Effective Immediately— NEW ORLEANS and CHERRY HILL, N.J. , July 17, 2023 /PRNewswire/ -- AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio's StemoniX subsidiary.

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist from the exchange.

Vyant Bio to pursue listing on OTC Pink Open Market

CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. As previously announced on April 24, 2023, Vyant Bio notified The Nasdaq Stock Market LLC of its intention to voluntarily delist its shares of common stock, par value $0.0001 per share (the “Common Stock”) from the Nasdaq Capital Market (“Nasdaq”) and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration

Vyant Bio (NASDAQ: VYNT ) stock is taking a beating on Tuesday after the biotechnology company announced plans to delist its shares. According to a press release, the company's Board of Directors determined that a voluntary delisting of shares was in order.

Why Is Vyant Bio (VYNT) Stock Down 35% Today?

CHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that on April 24, 2023 its Board of Directors determined it was appropriate to voluntarily delist its securities from The Nasdaq Capital Market (“Nasdaq”).

Vyant Bio Announces Voluntary Nasdaq Delisting and SEC Deregistration

Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agreed in principle to step down from their respective positions, effective today, February 3, to preserve cash for the execution of an orderly wind-down process.  Roberts will remain a member of the board of directors, while chief financial officer Andrew LaFrence will assume the position of president CEO to lead the company through the period of transition, New Jersey-based Vyant said in a statement.

Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives

Continu ing to E xplore S trategic A lternatives

Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force

Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. The biotechnology company also said it is participating in BIO's One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.

Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value

CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value.

Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives

Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Dr. Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Operator Thank you for standing by.

Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript

“Targeting specific functional rescue in a Rett patient cortical organoid disease model”

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience

CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that the Company has received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market.

Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at least the end of 2023. The company had $9.4 million of cash and equivalents as of September 30.

Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show

Vyant Bio (NASDAQ:VYNT) Inc senior scientist Matthew Green delivered poster presentations this week at the Loulou Foundation's CDKL5 forum held in Boston.  CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a rare neurodevelopmental condition caused by pathogenic mutations in the CDKL5 gene.

Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical conference

CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning to identify and validate drug targets and therapeutic candidates. Today, Vyant Bio provided key takeaways from its Platform and Poster presentations delivered by Matthew Green, Ph.D., Vyant Bio's Senior Scientist, at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7th and 8th, 2022, in Boston, MA. CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a rare neurodevelopmental condition caused by pathogenic mutations in the CDKL5 gene. The most common symptoms include early-onset, difficult to control seizures and neurodevelopmental impairment that affects cognitive, motor, speech and visual function.

Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation

Charity Event to Drive Awareness and Support Rett Families Around the World

Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala'

Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, allowing Reaction to expand its suite of drug discovery services. According to Vyant Bio (NASDAQ:VYNT), Reaction will retain US personnel at vivoPharm, located in Hershey, Pennsylvania, which includes in vitro and in vivo capabilities.

Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million

~ Reaction Biology Acquire s the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~

Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary

P latform and P oster Presentation s on Vyant Bio's Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD)

News for Vyant Bio Stock (VYNT)